title: Effects of botulinum toxin type A for spastic foot in post-stroke patients enrolled in a rehabilitation program.
abstract: The objective of this study was to evaluate the effects of botulinum toxin type A (BTX-A) on spastic foot in stroke patients in a rehabilitation program.
  
  
  METHODS
  Hemiparetic stroke patients (n=21) enrolled in a rehabilitation program were divided into two groups. The first group (n=11) received a total of 300 UI BTX-A, and the second group (n=10) received 100 UI BTX-A. All patients were assessed at baseline and 2, 4, 8 and 12 weeks after injection for Modified Ashworth Score, time walking 10 meters, and the Functional Independence Measure (mFIM) motor score.
  
  
  RESULTS
  The higher-dose group exhibited a significant improvement in spasticity, and both groups showed an improvement in time walking 10 meters and mFIM, with no significant differences between them.
  
  
  CONCLUSIONS
  Our findings suggest that gains in gait velocity and functional independence were not correlated to BTX-A dose.
authors.affiliation: Centro Integrado de Reabilitação, TeresinaPI, Brazil.
authors.forename: Leonardo Halley Carvalho
authors.initials: LH
authors.lastname: Pimentel
authors.affiliation: Centro Integrado de Reabilitação, TeresinaPI, Brazil.
authors.forename: Francisco José
authors.initials: FJ
authors.lastname: Alencar
authors.affiliation: Centro Integrado de Reabilitação, TeresinaPI, Brazil.
authors.forename: Leonardo Raphael Santos
authors.initials: LR
authors.lastname: Rodrigues
authors.affiliation: Departamento de Fisiologia e Farmacologia, Universidade Federal do Ceará, FortalezaCE, Brazil.
authors.forename: Francisca Cléa Florenço de
authors.initials: FC
authors.lastname: Sousa
authors.affiliation: Departamento de Medicina Comunitária, Universidade Federal do Piauí, TeresinaPI, Brazil.
authors.forename: João Batista Mendes
authors.initials: JB
authors.lastname: Teles
mesh_terms: D000203:Activities of Daily Living; D000328:Adult; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D005260:Female; D005534:Foot Diseases / Q000188:drug therapy* / Q000209:etiology; D005684:Gait / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009043:Motor Activity / Q000187:drug effects; D009128:Muscle Spasticity / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D018709:Statistics, Nonparametric; D020521:Stroke / Q000150:complications; D000071939:Stroke Rehabilitation; D013997:Time Factors; D016896:Treatment Outcome; D016138:Walking / Q000502:physiology
chemical_list: D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A